New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 22, 2013
08:40 EDTALXNAlexion gets positive CHMP opinion on extended indication for eculizumab
The EMA's Committee for Medicinal Products for Human Use adopted a positive opinion recommending a variation to the terms of the marketing authorization for the medicinal product Soliris. The marketing authorization holder for this medicinal product is Alexion Europe SAS. Soliris is currently authorized for the treatment of paroxysmal nocturnal haemoglobinuria in adults only and atypical haemolytic uremic syndrome in adults and children. The CHMPís opinion now recommends that the PNH indication be extended to include children, the EMA announced.
News For ALXN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2015
07:53 EDTALXNFDA PDUFA Date for Alexion's Asfotase Alfa is September 2, 2015
Subscribe for More Information
September 1, 2015
17:57 EDTALXNAlexion CEO sees slow sales uptake for Kanuma, Strensiq, Reuters says
In a Reuters interview following EU approval of the company's Strensiq and Kanuma treatments, Alexion CEO David Hallal said he expects a slow sales uptake for the two drugs, adding that boosting disease awareness and finding patients is a challenge. "It takes time to reach the patients and the physicians. When we launch, it's usually one patient at a time," said Hallal. The CEO also remarked that the company is targeting similar pricing between the U.S. and elsewhere. Reference Link
05:39 EDTALXNAlexion granted marketing authorization for Kanuma in EU
Subscribe for More Information
05:38 EDTALXNAlexion granted marketing authorization for Strensiq in EU
Subscribe for More Information
August 31, 2015
19:28 EDTALXNAlexion initiated with a Strong Buy at Raymond James
Target $225.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use